Monday, May 25, 2026
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Medicine

UC Irvine-led team engineers new enzyme to produce synthetic genetic material

October 9, 2024
in Medicine
Reading Time: 3 mins read
0
john chaput

“This is just the beginning,” says John Chaput, UC Irvine professor of pharmaceutical sciences. “We’re not just improving on existing drugs. We’re developing a whole new platform for creating therapies that aren’t possible with current technology.” Steve Zylius / UC Irvine

74
SHARES
669
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

A research team led by the University of California, Irvine has engineered an efficient new enzyme that can produce a synthetic genetic material called threose nucleic acid. The ability to synthesize artificial chains of TNA, which is inherently more stable than DNA, advances the discovery of potentially more powerful, precise therapeutic options to treat cancer and autoimmune, metabolic and infectious diseases.

blank
“This is just the beginning,” says John Chaput, UC Irvine professor of pharmaceutical sciences. “We’re not just improving on existing drugs. We’re developing a whole new platform for creating therapies that aren’t possible with current technology.” Steve Zylius / UC Irvine

A paper recently published in Nature Catalysis describes how the team created an enzyme called 10-92 that achieves faithful and fast TNA synthesis, overcoming key challenges in previous enzyme design strategies. Inching ever closer to the capability of natural DNA synthesis, the 10-92 TNA polymerase facilitates the development of future TNA drugs.

DNA polymerases are enzymes that replicate organisms’ genomes by accurately and efficiently copying DNA. They play vital roles in biotechnology and healthcare, as seen in the fight against COVID-19, in which they were crucial to pathogen detection and eventual treatment using the mRNA vaccine.

“This achievement represents a major milestone in the evolution of synthetic biology and opens up exciting possibilities for new therapeutic applications by significantly narrowing the performance gap between natural and artificial enzyme systems,” said corresponding author John Chaput, UC Irvine professor of pharmaceutical sciences. “Unlike DNA, TNA’s biostability allows it to be used in a much broader range of treatments, and the new 10-92 TNA polymerase will enable us to reach that goal.”

The team produced the 10-92 TNA polymerase using a technique called homologous recombination, which rearranges polymerase fragments from related species of archaebacteria. Through repeated cycles of evolution, the researchers identified polymerase variants with increasing activity, ultimately resulting in a variant that’s within the range of natural enzymes.

“Drugs of the future could look very different than those we use today,” Chaput said. “TNA’s resilience to enzymatic and chemical degradation positions it as the ideal candidate for developing new treatments such as therapeutic aptamers, a promising drug class that binds to target molecules with high specificity. Engineering enzymes that facilitate the discovery of new approaches could address the limitations of antibodies, such as improved tissue penetration, and potentially have an even greater positive impact on human health.”

Other UC Irvine team members were graduate students Victoria A. Maola, Eric J. Yik and Mohammad Hajjar; project scientist Nicholas Chim; and undergraduates Joy J. Lee, Kalvin K. Nguyen, Jenny V. Medina, Riley N. Quijano, Manuel J. Holguin and Katherine L. Ho – all from the Department of Pharmaceutical Sciences.

This work was supported by a grant from the National Science Foundation, under award MCB1946312. John Chaput, Victoria Maola, Eric Yik and UC Irvine have filed a patent application (PCT/US24/1159) on the composition and activity of the 10-92 TNA polymerase. The other authors declared no competing interests.

UC Irvine’s Brilliant Future campaign: Publicly launched on Oct. 4, 2019, the Brilliant Future campaign aims to raise awareness and support for the university. By engaging 75,000 alumni and garnering $2 billion in philanthropic investment, UC Irvine seeks to reach new heights of excellence in student success, health and wellness, research and more. The School of Pharmacy & Pharmaceutical Sciences plays a vital role in the success of the campaign. Learn more by visiting https://brilliantfuture.uci.edu/school-of-pharmacy-and-pharmaceutical-sciences.

About the University of California, Irvine: Founded in 1965, UC Irvine is a member of the prestigious Association of American Universities and is ranked among the nation’s top 10 public universities by U.S. News & World Report. The campus has produced five Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UC Irvine has more than 36,000 students and offers 224 degree programs. It’s located in one of the world’s safest and most economically vibrant communities and is Orange County’s second-largest employer, contributing $7 billion annually to the local economy and $8 billion statewide. For more on UC Irvine, visit www.uci.edu.

Media access: Radio programs/stations may, for a fee, use an on-campus studio with a Comrex IP audio codec to interview UC Irvine faculty and experts, subject to availability and university approval. For more UC Irvine news, visit news.uci.edu. Additional resources for journalists may be found at https://news.uci.edu/media-resources.

Journal Reference:

Victoria A. Maola, Eric J. Yik, Mohammad Hajjar, Joy J. Lee, Manuel J. Holguin, Riley N. Quijano, Kalvin K. Nguyen, Katherine L. Ho, Jenny V. Medina, Nicholas Chim, John C. Chaput. Directed evolution of a highly efficient TNA polymerase achieved by homologous recombination. Nature Catalysis, 2024; DOI: 10.1038/s41929-024-01233-1

Journal

Nature Catalysis

DOI

10.1038/s41929-024-01233-1 

Article Title

Directed evolution of a highly efficient TNA polymerase achieved by homologous recombination

Article Publication Date

1-Oct-2024

Share30Tweet19
Previous Post

Experimental Blood Test Improves Early Detection of Pancreatic Cancer

Next Post

UMSOM launches new rural health initiative to address physician shortage on Maryland’s Eastern Shore

Related Posts

RBM20 Isoform Control Shapes Splicing in Health — Medicine
Medicine

RBM20 Isoform Control Shapes Splicing in Health

May 24, 2026
ZNF274 Blocks Lineage Switch, Fuels CDK7 Drug Resistance — Medicine
Medicine

ZNF274 Blocks Lineage Switch, Fuels CDK7 Drug Resistance

May 24, 2026
Evaluating School Policies During COVID-19 Pandemic — Medicine
Medicine

Evaluating School Policies During COVID-19 Pandemic

May 24, 2026
Deep Phenotyping Reveals Skin Remodeling in Sclerosis Treatment — Medicine
Medicine

Deep Phenotyping Reveals Skin Remodeling in Sclerosis Treatment

May 23, 2026
Chewing, Nutrition, and Frailty in Elderly Patients — Medicine
Medicine

Chewing, Nutrition, and Frailty in Elderly Patients

May 23, 2026
Fish Consumption and Mercury Exposure in Chicago Asians — Medicine
Medicine

Fish Consumption and Mercury Exposure in Chicago Asians

May 23, 2026
Next Post
Low Res R HEALE Banner Dirt Road

UMSOM launches new rural health initiative to address physician shortage on Maryland's Eastern Shore

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27649 shares
    Share 11056 Tweet 6910
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    1052 shares
    Share 421 Tweet 263
  • Bee body mass, pathogens and local climate influence heat tolerance

    680 shares
    Share 272 Tweet 170
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    543 shares
    Share 217 Tweet 136
  • Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function

    529 shares
    Share 212 Tweet 132
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Tiny Blue Octopus from the Galápagos Islands: Small Enough to Fit in the Palm of Your Hand
  • Stabilizing Fractional Dynamics Suppress Epileptic Seizures
  • AI Insights Uncover Causes of Injury Deaths
  • Comparing Robust Intelligent Controls for 3-DOF Robots

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Biotechnology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Editorial Policy
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.

Join 5,146 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine